Antiresorptive and Anabolic Bone Therapy Does not Improve Weight Bearing Capacity and Bone Strength in OA Rats
Send a publication request
close

Publication request

Thank you for your interest in our product range and your request for this publication, which will be sent to you if the research team and the journal allow it. Our commercial team will contact you as soon as possible.




Authors
Cedo M. Bagi,corresponding author Edwin Berryman, David E. Zakur, Dean Wilkie, and Catharine J. Andresen


Lab
Comparative Medicine, Global Science and Technology, Pfizer Global Research and Development, Pfizer Inc., 100 Eastern Point Road, Groton, CT 06340 USA

Journal
Arthritis Res Ther.

Abstract
Osteoarthritis (OA) is a leading cause of disability, but despite the high unmet clinical need and extensive research seeking dependable therapeutic interventions, no proven disease-modifying treatment for OA is currently available. Due to the close interaction and interplay between the articular cartilage and the subchondral bone plate, it has been hypothesized that antiresorptive drugs can also reduce cartilage degradation, inhibit excessive turnover of the subchondral bone plate, prevent osteophyte formation, and/or that bone anabolic drugs might also stimulate cartilage synthesis by chondrocytes and preserve cartilage integrity. The benefit of intensive zoledronate (Zol) and parathyroid hormone (PTH) therapy for bone and cartilage metabolism was evaluated in a rat model of OA.

BIOSEB Instruments Used:
Static Weight Bearing Touch: Incapacitance Test (BIO-SWB-TOUCH-M)

Share this content